Table 1 Patient characteristics
Patients without | Patients with | |||
|---|---|---|---|---|
post-transplant adverse events | ||||
n = 13 | n = 48 | |||
No. [%] | No. [%] | |||
Sex | ||||
Male | 7 | (53.8) | 29 | (60.4) |
Female | 6 | (46.2) | 19 | (39.6) |
Age group | ||||
<6 y | 6 | (46.2) | 15 | (31.3) |
6–12 y | 3 | (23.1) | 18 | (37.5) |
13–26 y | 4 | (30.8) | 15 | (31.3) |
Donor | ||||
MUD | 3 | (23.1) | 13 | (27.1) |
MMFD | 7 | (53.8) | 31 | (64.6) |
MFD | 1 | (7.7) | 4 | (8.3) |
Autologous | 2 | (15.4) | 0 | (0.0) |
Primary diagnosis | ||||
ALL | 1 | (7.7) | 11 | (22.9) |
ALL relapse | 0 | (0.0) | 11 | (22.9) |
AML | 0 | (0.0) | 3 | (6.3) |
AML relapse | 1 | (7.7) | 4 | (8.3) |
CML | 1 | (7.7) | 2 | (4.2) |
JMML | 1 | (7.7) | 1 | (2.1) |
MDS | 0 | (0.0) | 4 | (8.3) |
T-NHL | 0 | (0.0) | 1 | (2.1) |
Solid tumors | 3 | (23.1) | 3 | (6.3) |
Aplastic anemia | 0 | (0.0) | 1 | (2.1) |
Neurometabolic disease | 1 | (7.7) | 3 | (6.3) |
Immunologic disease | 2 | (15.4) | 3 | (6.3) |
Autoimmune disease | 2 | (15.4) | 0 | (0.0) |
Chédiak-Higashi syndrome | 1 | (7.7) | 0 | (0.0) |
Kostmann disease | 0 | (0.0) | 1 | (2.1) |
Neurologic disease | 0 | (0.0) | 0 | (0.0) |
Radiation | ||||
TLI | 0 | (0.0) | 3 | (6.3) |
TBI | 1 | (7.7) | 7 | (14.6) |
GvHD prophylaxis | ||||
CsA + MTX | 3 | (23.1) | 11 | (22.9) |
CsA | 1 | (7.7) | 6 | (12.5) |
Acute GvHD | ||||
Grade I | 0 | (0.0) | 11 | (22.9) |
Grade II | 0 | (0.0) | 9 | (18.8) |
Grade III | 0 | (0.0) | 3 | (6.3) |
Grade IV | 0 | (0.0) | 1 | (2.1) |